Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Graphite Bio, Inc.
  6. Summary
    GRPH   US38870X1046

GRAPHITE BIO, INC.

(GRPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
12.42(c) 12.83(c) 12.9(c) 12.69(c) 12.32(c) Last
308 568 124 329 117 709 107 690 85 344 Volume
-2.82% +3.30% +0.55% -1.63% -2.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -68,9 M - -
Net cash position 2021 105 M - -
P/E ratio 2021 -6,29x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -94,7 M - -
Net cash position 2022 4,08 M - -
P/E ratio 2022 -7,77x
Yield 2022 -
Capitalization 716 M 716 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 49
Free-Float 90,5%
More Financials
Company
Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach... 
More about the company
All news about GRAPHITE BIO, INC.
10/21GRAPHITE BIO : Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
BU
10/12GRAPHITE BIO : Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th ..
BU
10/12Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease At 49Th..
CI
10/05GRAPHITE BIO : Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Associat..
BU
09/20GRAPHITE BIO, INC.(NASDAQGM : GRPH) added to S&P TMI Index
CI
08/30GRAPHITE BIO : Announces Participation in Upcoming September Investor Conferences
BU
08/12GRAPHITE BIO : Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
08/12GRAPHITE BIO : Reports Recent Business Progress and Second Quarter 2021 Financial Results ..
PU
08/12GRAPHITE BIO, INC. : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/12GRAPHITE BIO : Reports Recent Business Progress and Second Quarter 2021 Financial Results
BU
08/12Graphite Bio, Inc. Announces Earnings Results for the Quarter and Six Months Ended June..
CI
07/20GRAPHITE BIO : Morgan Stanley Initiates Coverage on Graphite Bio With Overweight Rating, $..
MT
07/20GRAPHITE BIO : SVB Leerink Starts Graphite Bio at Outperform With $34 Price Target
MT
07/20GRAPHITE BIO : BofA Securities Initiates Coverage on Graphite Bio With Buy Rating, $35 Pri..
MT
07/20GRAPHITE BIO : Cowen Initiates Coverage on Graphite Bio With Outperform Rating
MT
More news
News in other languages on GRAPHITE BIO, INC.

- No features available -

More news
Analyst Recommendations on GRAPHITE BIO, INC.
More recommendations
Chart GRAPHITE BIO, INC.
Duration : Period :
Graphite Bio, Inc. Technical Analysis Chart | GRPH | US38870X1046 | MarketScreener
Technical analysis trends GRAPHITE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 12,32 $
Average target price 34,67 $
Spread / Average Target 181%
EPS Revisions
Managers and Directors
Joshua Lehrer-Graiwer President, Chief Executive Officer & Director
Phillip P. Gutry Chief Business Officer & Head-Finance
Perry A. Karsen Chairman
Jerry Cacia Chief Technical Officer
Jane Grogan Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GRAPHITE BIO, INC.0.00%716
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610